|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CXorf56 |
Gene summary for CXORF56 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CXorf56 | Gene ID | 63932 |
| Gene name | STING1 ER exit protein 1 | |
| Gene Alias | CXorf56 | |
| Cytomap | Xq24 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9H5V9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 63932 | CXorf56 | LZE4T | Human | Esophagus | ESCC | 4.85e-02 | 1.07e-01 | 0.0811 |
| 63932 | CXorf56 | LZE7T | Human | Esophagus | ESCC | 3.74e-05 | 4.26e-01 | 0.0667 |
| 63932 | CXorf56 | LZE24T | Human | Esophagus | ESCC | 2.17e-09 | 2.90e-01 | 0.0596 |
| 63932 | CXorf56 | P2T-E | Human | Esophagus | ESCC | 4.61e-25 | 3.43e-01 | 0.1177 |
| 63932 | CXorf56 | P4T-E | Human | Esophagus | ESCC | 4.32e-11 | 1.89e-01 | 0.1323 |
| 63932 | CXorf56 | P5T-E | Human | Esophagus | ESCC | 1.16e-13 | 9.08e-02 | 0.1327 |
| 63932 | CXorf56 | P8T-E | Human | Esophagus | ESCC | 2.56e-14 | 1.79e-01 | 0.0889 |
| 63932 | CXorf56 | P9T-E | Human | Esophagus | ESCC | 1.56e-06 | 7.72e-02 | 0.1131 |
| 63932 | CXorf56 | P10T-E | Human | Esophagus | ESCC | 2.49e-17 | 2.94e-01 | 0.116 |
| 63932 | CXorf56 | P12T-E | Human | Esophagus | ESCC | 1.23e-12 | 1.06e-01 | 0.1122 |
| 63932 | CXorf56 | P15T-E | Human | Esophagus | ESCC | 8.48e-05 | 1.27e-01 | 0.1149 |
| 63932 | CXorf56 | P16T-E | Human | Esophagus | ESCC | 6.08e-19 | 1.07e-01 | 0.1153 |
| 63932 | CXorf56 | P20T-E | Human | Esophagus | ESCC | 3.28e-08 | 1.49e-01 | 0.1124 |
| 63932 | CXorf56 | P21T-E | Human | Esophagus | ESCC | 4.21e-13 | 2.69e-01 | 0.1617 |
| 63932 | CXorf56 | P22T-E | Human | Esophagus | ESCC | 1.01e-10 | 2.19e-01 | 0.1236 |
| 63932 | CXorf56 | P23T-E | Human | Esophagus | ESCC | 1.23e-12 | 3.35e-01 | 0.108 |
| 63932 | CXorf56 | P24T-E | Human | Esophagus | ESCC | 7.77e-06 | 9.42e-02 | 0.1287 |
| 63932 | CXorf56 | P26T-E | Human | Esophagus | ESCC | 8.79e-13 | 2.62e-01 | 0.1276 |
| 63932 | CXorf56 | P27T-E | Human | Esophagus | ESCC | 2.28e-08 | 1.10e-01 | 0.1055 |
| 63932 | CXorf56 | P28T-E | Human | Esophagus | ESCC | 2.14e-15 | 8.65e-02 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CXorf56 | SNV | Missense_Mutation | c.200A>C | p.Lys67Thr | p.K67T | Q9H5V9 | protein_coding | deleterious(0) | possibly_damaging(0.732) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CXorf56 | SNV | Missense_Mutation | novel | c.454G>A | p.Glu152Lys | p.E152K | Q9H5V9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CXorf56 | SNV | Missense_Mutation | novel | c.445N>A | p.Asp149Asn | p.D149N | Q9H5V9 | protein_coding | deleterious(0.01) | possibly_damaging(0.841) | TCGA-AA-3819-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CXorf56 | SNV | Missense_Mutation | novel | c.112N>C | p.Val38Leu | p.V38L | Q9H5V9 | protein_coding | tolerated(0.05) | benign(0.255) | TCGA-AA-3831-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CXorf56 | SNV | Missense_Mutation | c.287C>T | p.Pro96Leu | p.P96L | Q9H5V9 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| CXorf56 | SNV | Missense_Mutation | novel | c.79C>A | p.Leu27Ile | p.L27I | Q9H5V9 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CXorf56 | SNV | Missense_Mutation | rs764134233 | c.587N>T | p.Ala196Val | p.A196V | Q9H5V9 | protein_coding | tolerated(0.18) | benign(0.281) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| CXorf56 | SNV | Missense_Mutation | c.227N>A | p.Thr76Asn | p.T76N | Q9H5V9 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CXorf56 | SNV | Missense_Mutation | novel | c.13N>A | p.Val5Met | p.V5M | Q9H5V9 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CXorf56 | SNV | Missense_Mutation | novel | c.540N>T | p.Met180Ile | p.M180I | Q9H5V9 | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |